drugset / Trial / NCT02013102
A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate of the safety and efficacy of decitabine treatment of Myelodysplastic Syndrome.
Timeline
- Start
- 2013-03
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 12 mg/m2 | Intravenous |
| Subject | Decitabine | Small molecule | 20 mg/m2 | Intravenous |